Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Bavarian Nordic

Biotech & Life Sciences · Gentofte Municipality, Denmark · Founded 1994 · IPO 1998 Unicorn

Biopharmaceutical company developing cancer immunotherapies and vaccines against infectious diseases

Valuation
$1.64B
Market cap · May/2026
Revenue
$916M
Latest reported FY
EBITDA
$206M
Latest reported FY

Global footprint

Where Bavarian Nordic has talent and traffic

AI talent share
0.1% of workforce is AI talent
(2 of 1,730 staff)
Core AI00%
Other AI20.12%
Non-AI workforce1,72899.88%
Workforce by country
19 countries with
team presence
🇩🇰 Denmark59.8%
🇩🇪 Germany14.2%
🇨🇭 Switzerland13.4%
🇺🇸 United States8.3%
🇨🇦 Canada1.2%
Top 5 of 19 shown

Patent intelligence

$111M patent portfolio · 70 active families

Estimated portfolio value
$111M
6.8% of market cap · 4.8× the top peer SpringWorks Therapeutics ($23M)
70 active patent families
Where Bavarian Nordic innovates CarcinosisBiomedical engineeringTGE VACCINEDouble strandCancer research

Where Bavarian Nordic concentrates vs peers

Each axis is a top-10 topic across Bavarian Nordic and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Bavarian Nordic

An AI-synthesized read of the highest-engagement posts about Bavarian Nordic on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Bavarian Nordic on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.